



Training

Numerus's course "AMNOG-Related Statistics" provides detailed answers to questions such as:

- What are the statistical advantages and disadvantages of OR, RR and RD and how are the values to be interpreted? If an effect estimator is specified in the dossier, which is the most appropriate and why does IQWiG place so much value on the RR?
- What is a Hedges' g, what is actually calculated and why is this value a sign of clinical relevance?
- Explanation of Kaplan-Meier estimates, survival curves and their interpretation.
- Subgroup analyses: How is an interaction p-value calculated, what does this value actually say? Basic problems of subgroup analyses carried out post-hoc and the interpretation of the results.

The course can be tailored to meet your individual requirements and can be delivered on or off-site.

Numerus also provides training and guidance based on IQWiG guidelines, preparing companies for meetings with the G-BA.

Numerus's statisticians are internationally located, provide multilingual support and have a solid understanding of the ever changing country specific guidelines.

When speed, accuracy and quality are paramount you can depend on Numerus to deliver.

Expert analyses & advice delivered on-time and in budget



Contact us!

www.numerus.com

Email: bd@numerus.com

Phone: +49 (0)7121 1372 936

Numerus GmbH
Lederstraße 78,
72764 Reutlingen,
Germany

numerus

Discover the power of statistics

Statistical Expertise for AMNOG Submissions to the G-BA (Germany)





Strategic Consultancy

Based on a thorough assessment of your value strategy we identify which analyses to present to the G-BA. We look at existing material, perform a GAP analysis and report what is missing and what the G-BA are likely to demand. We then provide the analyses in a format that can be conveniently inserted into module 4 of the dossier and its appendices.

The Value to You

Interpreting what the G-BA guidelines require you to submit in your dossier can be challenging. Rather than risk having the G-BA reject your dossier as incomplete the temptation may be to include everything - a massive task.

Numerus not only understands the appropriate statistical methodology acceptable to the G-BA. We have the knowledge that comes from our years of experience in preparing these analyses, enabling us to focus on what the G-BA really want to see.

We can reduce the burden of work while minimising the risk that something will be considered "missing". We can anticipate and advise on possible requests, saving time and stress by performing these in advance and having them in readiness should they be requested.

The Numerus Advantage



Highly specialised and focused on HTA statistics. We've supported AMNOG submissions since 2012 (Germany)



In-depth know-how of German healthcare authorities, guidelines and procedures



Unique cutting-edge analytical approach and outstanding methodological skills



Straightforward and enthusiastic business partner delivering operational flexibility and speed



HTA Analytical Services

- Systematic literature review & data extraction
- Evidence synthesis
- Network meta-analysis
- Indirect treatment comparison
- Bayesian belief network / DAG
- Simulated treatment comparison
- Event forecasting & prediction
- Matching-adjusted indirect comparison

Visualising Analytical Results

The benefit assessment for a new drug often requires reviewing hundreds if not thousands of analyses. The obligatory interaction and subgroup analyses required by IQWiG and the G-BA significantly inflate the number of statistical analyses to be performed, increasing the chance of postulating an effect that does not exist in reality.

Numerus has addressed this challenge by developing the Interaction Explorer Board, an interactive online tool that allows the user to visually explore risks and opportunities among subgroup interaction analyses. To see a demonstration visit:

<https://de.numerus.com/IEBfree>

